IL-2 antibodies in type 1 diabetes and during IL-2 therapy

被引：6

作者：

Churlaud, Guillaume ^{[1
,2
,3
]}

Rosenzwajg, Michelle ^{[1
,2
,3
]}

Cacoub, Patrice ^{[1
,2
,3
,4
]}

Saadoun, David ^{[1
,2
,3
,4
]}

Valteau-Couanet, Dominique ^{[5
]}

Chaput, Nathalie ^{[6
,7
,8
]}

Pugliese, Alberto ^{[9
,10
,11
]}

Klatzmann, David ^{[1
,2
,3
]}

机构：

[1] Grp Hosp Pitie Salpetriere, AP HP, Biotherapy CIC BTi, Paris, France

[2] Inflammat Immunopathol Biotherapy Dept i2B, Paris, France

[3] Sorbonne Univ, INSERM, Immunol Immunopathol Immunotherapy, 83 Bd Hop, F-75651 Paris, France

[4] Grp Hosp Pitie Salpetriere, AP HP, Dept Internal Med & Clin Immunol, Natl Reference Ctr Autoimmune Syst & Rare Dis, Paris, France

[5] Gustave Roussy, Dept Pediat, Villejuif, France

[6] Inst Gustave Roussy, CNRS, UMS 3655, Inst Gustave Roussy,Lab Immunomonitoring Oncol, Villejuif, France

[7] INSERM, US23, Villejuif, France

[8] Univ Paris Sud, UFR Pharm, Chatenay Malabry, France

[9] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA

[10] Univ Miami, Miller Sch Med, Dept Med, Div Endocrinol & Metab, Miami, FL 33136 USA

[11] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA

来源：

DIABETOLOGIA | 2018年 / 61卷 / 09期

关键词：

Autoantibodies; Autoimmune disease; Autoimmunity; IL-2; Type; 1; diabetes; LOW-DOSE INTERLEUKIN-2; BINDING; PHASE; SERA;

D O I：

10.1007/s00125-018-4649-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2066 / 2068

页数：3

共 50 条

[11] Renoprotection by IL-2/IL-2 antibody complexes
Nature Reviews Nephrology, 2012, 8 (8) : 434 - 434
[12] IL-2, IL-2 RECEPTORS AND HUMAN RETROVIRUSES
GREENE, WC
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 469 - 470
[13] Neutralizing IL-2 antibodies enhance in vivo IL-2 activity by prolonging its half-life and reducing IL-2 binding to IL-2 receptor-expressing cells
Bouchaud, G.
Krieg, C.
Boyman, O.
ALLERGOLOGIE, 2011, 34 (02) : 100 - 100
[14] Selectively Agonizing Treg in Type 1 Diabetes with IL-2 Muteins
Khoryati, Liliane
Kumari, Swarnima
Pham, Thi Minh Nguyet
Bogdani, Marika
Gavin, Marc
DIABETES, 2018, 67
[15] Response to IL-2 signalling is specifically impaired in type 1 diabetes
Prietl, B.
Kofler, S.
Stanzer, S.
Brezinsek, H.
Munzker, J.
Pieber, T.
Sourij, H.
DIABETOLOGIA, 2017, 60 : S204 - S204
[16] INTERLEUKIN 2 (IL-2) ACTIVITY DURING TUMOR-GROWTH - IL-2 PRODUCTION KINETICS, ABSORPTION OF AND RESPONSES TO EXOGENOUS IL-2
BURGER, CJ
ELGERT, KD
FARRAR, WL
CELLULAR IMMUNOLOGY, 1984, 84 (02) : 228 - 239
[17] INTERLEUKIN-2 (IL-2) UPREGULATES IL-2 RECEPTOR EXPRESSION - EVIDENCE THAT IL-2 AUGMENTS IL-2 RECEPTOR MESSENGER-RNA
DEPPER, J
LEONARD, W
DROGULA, C
KRONKE, M
WALDMANN, T
GREENE, W
FEDERATION PROCEEDINGS, 1985, 44 (03) : 786 - 786
[18] Cytokine production, IL-2 surface and soluble receptors during IL-2 treatment
Dmoszynska, A
Kandefer-Szerszen, M
Legiec, W
Rolinski, J
Kaminska, T
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 82 - 82
[19] THE IL-2/IL-2 RECEPTOR SYSTEM - A CURRENT OVERVIEW
TANIGUCHI, T
MINAMI, Y
CELL, 1993, 73 (01) : 5 - 8
[20] Reversible lymphocyte anergy during IL-2 therapy
Fortis, T
Clementi, E
IMMUNOLOGY TODAY, 1997, 18 (05): : 254 - 254

← 1 2 3 4 5 →